Follow the people · Insider
Robert Lechleider
Robert Lechleider files insider transactions with the SEC as a chief medical officer of Immunome (IMNM). We hold 2 disclosed purchases and sales filed since 31 October 2023, 2 of them in the last 90 days.
- Files forIMNM
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure27 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 27 October 2023 — 23 July 2026Chief Medical Officer · Immunome (IMNM)15 Form 4 lines · source: SEC Form 4
Everything they disclosed
15 entries, newest first — one per disclosure report, one per Form 4 line- was granted 54,000 shares of ImmunomeSEC Form 427 July 2026Common Stock · traded 23 July 2026 · filed 27 July 2026
- was granted 108,000 shares of Immunome (a derivative holding)SEC Form 427 July 2026Employee Stock Option (right to buy) · traded 23 July 2026 · filed 27 July 2026
- exercised options over 55,000 shares of ImmunomeSEC Form 47 July 2026Common Stock · traded 2 July 2026 · filed 7 July 2026
- ▼ sold on the open market 22,714 shares of ImmunomeSEC Form 47 July 2026Common Stock · traded 2 July 2026 · filed 7 July 2026
- ▼ sold on the open market 16,214 shares of ImmunomeSEC Form 47 July 2026Common Stock · traded 2 July 2026 · filed 7 July 2026
- ▼ sold on the open market 16,072 shares of ImmunomeSEC Form 47 July 2026Common Stock · traded 2 July 2026 · filed 7 July 2026
- exercised options over 55,000 shares of Immunome (a derivative holding)SEC Form 47 July 2026Employee Stock Option (right to buy) · traded 2 July 2026 · filed 7 July 2026
- exercised options over 55,000 shares of ImmunomeSEC Form 429 June 2026Common Stock · traded 25 June 2026 · filed 29 June 2026
- ▼ sold on the open market 40,580 shares of ImmunomeSEC Form 429 June 2026Common Stock · traded 25 June 2026 · filed 29 June 2026
- ▼ sold on the open market 14,420 shares of ImmunomeSEC Form 429 June 2026Common Stock · traded 25 June 2026 · filed 29 June 2026
- exercised options over 55,000 shares of Immunome (a derivative holding)SEC Form 429 June 2026Employee Stock Option (right to buy) · traded 25 June 2026 · filed 29 June 2026
- was granted 242,000 shares of Immunome (a derivative holding)SEC Form 431 July 2025Employee Stock Option (right to buy) · traded 29 July 2025 · filed 31 July 2025
- ▲ bought on the open market 15,805 shares of ImmunomeSEC Form 425 November 2024Common Stock · traded 21 November 2024 · filed 25 November 2024
- was granted 200,000 shares of Immunome (a derivative holding)SEC Form 413 August 2024Stock option (right to buy) · traded 9 August 2024 · filed 13 August 2024
- was granted 400,000 shares of Immunome (a derivative holding)SEC Form 431 October 2023Stock option (right to buy) · traded 27 October 2023 · filed 31 October 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.